Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Elgazzar - treatment, 2020 RCTivermectinhydroxychloroquineCOVID 19 hospitalizedhigh
200/200 suggested
  • suggested 93 % decrease in deaths but with a low degree of certainty due to high risk of bias
Hashim A, 2020
 
NCT04591600
RCTivermectinstandard of careCOVID 19 hospitalizedsome concern
70/70 inconclusive
  • inconclusive 52 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Soto-Becerra, 2020 OBSivermectinstandard of careCOVID 19 hospitalized, COVID-19 mild to moderatemoderate
203/2630 safety concern
  • inconclusive 39 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 58 % increase in death or transfer to ICU with a moderate degree of certainty due to some concern in risk of bias
Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin. The HCQ AZIT treatment seems to increase risk for all-cause death
ICON, 2020 OBSivermectinstandard of careCOVID 19 hospitalizedNA
173/107 suggested
  • suggested 53 % decrease in deaths (PE)

COVID-19 mild to moderate meta-analysis

Ahmed, 2020 RCTivermectinplaceboCOVID-19 mild to moderatehigh
48/24 suggested
  • suggested 3.1-fold increase in PCR-negative conversion (time to event analysis only),PCR-negative conversion (14-day) (PE) but with a low degree of certainty due to high risk of bias
Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
Chaccour, 2020
 
NCT04390022
RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in PCR-negative conversion,PCR-negative conversion (7-day) (PE) with a high degree of certainty due to low risk of bias
Chachar, 2020 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
25/25 inconclusive
  • inconclusive 19 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Krolewiecki, A, 2020
 
NCT04381884
RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
30/15 inconclusive
    Viral load reduction between baseline and day-5 was also similar between groups
    NCT04523831 (Mahmud), 2020
     
    NCT04523831
    RCTivermectinstandard of careCOVID-19 mild to moderatehigh
    200/200 safety concern
    • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
    • suggested 93 % increase in clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
    • suggested 56 % decrease in clinical deterioration but with a low degree of certainty due to high risk of bias
    • statistically significant 17.6-fold increase in adverse events but with a low degree of certainty due to high risk of bias
    results from clinicaltrial.gov
    Glorial F, 2020
     
    NCT04343092
    OBSivermectinstandard of careCOVID-19 mild to moderateNA
    6/71 inconclusive
    • inconclusive 10 % decrease in clinical improvement (PE)
    Khan, 2020 OBSivermectinstandard of careCOVID 19 hospitalized, COVID-19 mild to moderateNA
    115/133 suggested
    • suggested 88 % decrease in deaths
    • suggested 7.3-fold increase in clinical improvement
    • suggested 88 % decrease in ventilation
    Espitia-Hernandez, 2020 NRaivermectinstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
    28/7 suggested
    • suggested 714.0-fold increase in PCR-negative conversion
    Spoorthi, 2020 NRaivermectinplaceboCOVID 19 hospitalized, COVID-19 mild to moderateNA
    50/50 inconclusive

      COVID-19 severe or critically meta-analysis

      Niaee (vs placebo), 2020
       
      IRCT20200408046987N1
      RCTivermectincontrolCOVID-19 severe or criticallyhigh
      120/30 suggested
      • suggested 86 % decrease in deaths but with a low degree of certainty due to high risk of bias
      Okumuş, 2020
       
      NCT04646109
      RCTivermectincontrolCOVID-19 severe or criticallyNA
      30/30 inconclusive
        Camprubi, 2020 OBSivermectinstandard of careCOVID-19 severe or criticallyNA
        13/13 inconclusive

          COVID 19 outpatients meta-analysis

          Chowdhury A, 2020
           
          NCT04434144
          RCTivermectinhydroxychloroquine plus macrolidesCOVID 19 outpatientshigh
          60/56 no results
            Podder, 2020 RCTivermectinstandard of careCOVID 19 outpatientshigh
            32/30 inconclusive

              PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
              Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).